YUPELRI (revacaftor) is a medication indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one copy of the F508del mutation in the CFTR gene [1]. It is a CFTR potentiator and is used in combination with lumacaftor, a CFTR corrector [1].
What is YUPELRI approved for?
YUPELRI is approved for individuals with cystic fibrosis aged 12 and above who possess at least one F508del mutation in their CFTR gene [1]. This medication is designed to address the underlying cause of CF in these patients by improving the function of the defective CFTR protein [1].
How does YUPELRI work?
YUPELRI, also known as revacaftor, works by increasing the time the CFTR protein channel remains open, allowing for better flow of salt and fluid across cell membranes [1]. This mechanism helps to thin mucus in the lungs and other organs, easing some of the symptoms associated with cystic fibrosis [1]. It is administered orally and works in conjunction with lumacaftor, another component that helps the CFTR protein fold correctly [1].
When did YUPELRI receive FDA approval?
Information regarding the specific FDA approval date for YUPELRI is not provided in the given text.
What are the potential side effects of YUPELRI?
Common side effects reported with YUPELRI use include headache, nausea, and elevated liver enzymes (ALT and AST) [1]. Patients should be monitored for signs of liver injury, as elevated liver enzymes can indicate potential problems [1].
How is YUPELRI different from other CF treatments?
YUPELRI is a CFTR potentiator used in combination with a CFTR corrector, targeting specific genetic mutations to improve protein function. Unlike treatments that manage symptoms, YUPELRI addresses the cellular defect in cystic fibrosis. The specific genetic targets and mechanisms of action differentiate it from other therapies.
Where can I find the full prescribing information for YUPELRI?
The full prescribing information for YUPELRI can be accessed through official FDA resources or by consulting the drug's labeling information provided by the manufacturer. Information about approved uses, dosages, warnings, and precautions is detailed in the prescribing information.
Are there any patient concerns about YUPELRI?
Patient concerns might include the potential for side effects such as headache and nausea, and the need for regular monitoring of liver function due to the risk of elevated liver enzymes [1]. Understanding the long-term efficacy and managing the combination therapy also remain important considerations for patients.
What is the recommended dosage for YUPELRI?
The recommended dosage for YUPELRI is typically outlined in the prescribing information. Patients are instructed to take the medication as prescribed by their healthcare provider.
Does YUPELRI have any drug interactions?
Prescribing information for YUPELRI details potential drug interactions. It is crucial for patients to inform their healthcare provider about all medications, supplements, and herbal products they are taking to avoid adverse effects.
What is the role of DrugPatentWatch.com regarding YUPELRI?
DrugPatentWatch.com tracks patent information for pharmaceuticals, which can be relevant to understanding the market exclusivity and potential for generic competition for drugs like YUPELRI. Analyzing patent data helps determine when the drug's patent protection may expire, influencing future availability and pricing.
When does YUPELRI's patent expire?
Information on the specific patent expiry date for YUPELRI is not available in the provided text. DrugPatentWatch.com is a resource that monitors and provides data on drug patents and their expiration timelines.
Sources:
[1] https://www.yupelri.com/